ANG and ovarian carcinoma: We know that the most widely evaluated Ang inhibitor, trebananib, is active as a single agent (Herbst et al, 2009) in ovarian cancer, yet in phase III trials in biologically unselected patients, the drug was modestly active in one phase III trial (Monk et al, 2014).